Clinical trial
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the…
NCT00044512 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00044512 |
|---|---|
| Title | A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma |
| Official title | A Phase II Multicenter Uncontrolled Trial of Sorafenib (BAY43-9006) in Patients With Advanced Hepatocellular Carcinoma |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006) |
| Enrollment | 137 |
| Start date | Aug 1, 2002 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Sep 4, 2002 |
| Last update posted | Apr 16, 2014 |
| Countries | Belgium, France, Israel, Italy, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: